{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.82","upperLimit":"96.54","value":"93.01"},{"groupId":"OG001","lowerLimit":"3.84","upperLimit":"25.24","value":"10.12"}]}],"title":"≥ 50 ng/dL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.20","upperLimit":"63.16","value":"53.93"},{"groupId":"OG001","lowerLimit":"0.46","upperLimit":"20.77","value":"3.23"}]}],"title":"> 280 ng/dL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.97","upperLimit":"63.94","value":"54.73"},{"groupId":"OG001","lowerLimit":"0.46","upperLimit":"20.77","value":"3.23"}]}],"title":"> Baseline level or 280 ng/dL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"The cumulative probability of testosterone recovery back to \\> 280 ng/dL (lower limit of the normal range), back to ≥ 50 ng/dL (definition of castration), and back to \\> 280 ng/dL or baseline at 90 days after drug discontinuation was assessed. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least 1 dose of study drug and were followed in the testosterone recovery phase.","reportingStatus":"POSTED","timeFrame":"Day 90 follow-up","title":"Testosterone Recovery Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}